High prevalence of human papillomavirus infection in the female population of Guatemala

International Journal of Cancer

Volumn 125, Issue 5, 2009, Pages 1161-1167

  Vallès, Xavier ^a   Murga, Gladys Beatriz ^b   Hernández, Gabriela ^c   Sabidó, Meritxell ^d,e,f   Chuy, Alejandro ^b   Lloveras, Belén ^a   Alameda, Francesc ^f   De San José, Sílvia ^a,e   Bosch, Francesc Xavier ^a,e   Pedroza, Isabel ^g   Castellsagué, Xavier ^a,e   Casabona, Jordi ^d,e,f,h  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b Hospital Departamental de Escuintla   (Guatemala)

^c Microbiology Unit   (Guatemala)

^d Fundacio SIDA i Societat   (Spain)

^e CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^f UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^g IDIBELL ^*  (Guatemala)

^h CATALAN INSTITUTE OF ONCOLOGY   (Spain)

Author keywords

Abnormal cytology; Guatemala; Human papillomavirus; Prevalence; Sex workers

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; FEMALE; GENOTYPE; GUATEMALA; GYNECOLOGICAL EXAMINATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 66; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SMOKING; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VERRUCA VULGARIS; WART VIRUS;

ADOLESCENT; ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; COHORT STUDIES; DNA, VIRAL; FEMALE; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PREVALENCE; PROGNOSIS; RISK FACTORS; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 67650072666     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24444     Document Type: Article

References (33)

1. Ferlay F, Bray F, Pisani P, Parkin DM. Globocan 2002: cancer incidence, mortality and prevalence worldwide iarc cancer. Base No 5, Version 2.0. Lyon: International Agency for Research on Cancer (IARC) Press, 2004.
2. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19.
3. Bosch FX, de Sanjosé S. Chapter 1: human papilloma virus and cervical cancer-burden and assessment of causality. J Natl Cancer Inst Monogr 2003;31:3-13.
4. Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, Tortolero-Luna G, Kjaer SK, Muñoz N. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008;26 (Suppl 10):K1-K16.
5. Munoz N, Bosch F, de Sanjose S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer. N Engl J Med 2003;348:518-27.
6. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007;121:621-32.
7. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X, de Carvalho NS, Skinner SR, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomized controlled trial. Lancet 2007;369:2161-70.
8. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-43.
9. Perez G, Lazcano-Ponce E, Hernandez-Avila M, García PJ, Muñoz N, Villa LL, Bryan J, Taddeo FJ, Lu S, Esser MT, Vuocolo S, Sattler C, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women. Int J Cancer 2008;122:1311-8.
10. National STI/HIV/AIDS Programme UNGASS Commitment Progress Report. UNAIDS. 2006.
11. Sabidó M, Giardina F, Hernández G, Fernández VH, Monzón JE, Montoliu A, Casabona J. The UALE Project: decline in the incidence of HIV and sexually transmitted infections and increase in the use of condoms among sex workers in Guatemala. JAIDS 2009, in press.
12. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T, Jr, Young N;Forum Group Members; Bethesda 2001 Workshop. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA 2001;287:2140-1.
13. Coutlée F, Gravitt P, Komegay J, Hankins C, Richardson H, Lapointe N, Voyer H, Franco E. Use of PGMY primers in L1 consensus PCR improves detection of human papillomavirus DNA in genital samples. J Clin Microbiol 2002;40:902-7.
14. Hernandez BY, Nguyen TV. Cervical human papillomavirus infection among female sex workers in Southern Vietnam. Infect Agent Cancer 2008;3:7.
15. Yun H, Park J, Choi I, Kee M, Choi B, Kim S. Prevalence of human papillomavirus and Herpes Virus Type 2 infection in Korean commercial sex workers. J Microbiol Biotechnol 2008;18:350-4.
16. Rodriguez-Reyes ER, Quiñónez-Pérez JM, Cerda-Flores RM, Saucedo-Cardenas O, Cortés-Gutiérrez EI. Prevalence of HPV in sex workers in Durango, Mexico. Salud Pulbica Mex 2005;47:393.
17. Chandeying V, Garland SM, Tabrizi SN. Prevalence and typing of human papillomavirus (HPV) among female sex workers and outpatient women in Southern Thailand. Sex Health 2006;3:11-14.
18. Ortiz M, Torres M, Muñoz L, Fernández-García E, Canals J, Cabomero AL, Aguilar E, Ballesteros J, Del Amo J, Garcia-Sáiz A. Oncogenic human papillomavirus (HPV) type distribution and HPV Type 16 E6 variants in two Spanish population groups with different levels of HPV infection risk. J Clin Microbiol 2006;44:1428-34.
19. Didelot-Rousseau MN, Nagot N, Costes-Martineau V, Vallès X, Ouedraogo A, Konate I, Weiss HA, Van de Perre P, Mayaud P, Segondy M; Yerelon Study Group. Human papillomavirus genotype distribution and cervical squamous intraepithelial lesions among high-risk women with and without HIV-1 infection in Burkina Faso. Br J Cancer 2006;95:355-62.
20. de Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, Bosch FX. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007;7:453-9.
21. Herrero R, Castle PE, Schiffman M, bratti MC, Hildesheim A, Morales J, Alfaro M, Sherman ME, Wacholder S, Chen S, Rodriguez AC, Burk RD. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis 2005;191:1796-807.
22. Franceschi S, Herrero R, Clifford GM, Snijders PJ, Arslan A, Anh PT, Bosch FX, Ferreccio C, Hieu NT, Lazcano-Ponce E, Matos E, Molano M, et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 2006;119:2677-84.
23. Castellsague X, Bosch FX, Munoz N. Environmental co-factors in HPV carcinogenesis. Virus Res 2002;89:191-99.
24. Castellsagué X, Ghaffari A, Daniel RW, Bosch FX, Muñoz N, Shah KV. Prevalence of Penile human papillomavirus DNA in husbands of women with and without cervical neoplasia: a study in Spain and Colombia. J Infect Dis 1997;176:353-61.
25. Vaccarella S, Franceschi S, Herrero R, Muñoz N, Snijders PJ, Clifford GM, Smith JS, Lazcano-Ponce E, Sukvirach S, Shin HR, de Sanjosé S, Molano M, et al. Sexual behaviour, condom use, and human papillomavirus: pooled analysis of the IARC human papillomavirus prevalence surveys. Cancer Epidemiol Biomarkers Prev 2006;15:326-33.
26. Molano M, Posso H, Weiderpass E, van den Brule AJ, Ronderos M, Franceschi S, Meijer CJ, Arslan A, Munoz N; HPV Study Group. Prevalence and determinants of HPV infection among colombian women with normal cytology. Br J Cancer 2002;87:324-33.
27. Winer RL, Hughes JP, Feng Q, O'Reilly S, Kiviat NB, Holmes KK, Koutsky LA. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med 2006;354:2645-54.
28. Castellsagué X, Bosch FX, Muñoz N. The male role in cervical cancer. Salud Publica Mex 2003;45 Suppl 3:S345-S53.
29. Gravitt PE, Schiffman M, Solomon D, Wheeler CM, Castle PE. A comparison of linear array and hybrid capture 2 for detection of carcinogenic human papillomavirus and cervical precancer in ASCUS-LSIL triage study. Cancer Epidemiol Biomarkers Prev 2008;17:1248-54.
30. Monsonego J, Pollini G, Evrard MJ, Sednaoui P, Monfort L, Zerat L, Syrjänen K. Detection of human papillomavirus genotypes among high-risk women: a comparison of hybrid capture and linear arrays. Sex Transm Dis 2008;35:521-7.
31. Stevens MP, Garland SM, Rudland E, Tan J, Quinn MA, Tabrizi SN. Comparison of the digene hybrid capture 2 assay and Roche AMPLICOR and LINEAR ARRAY human papillomavirus (HPV) tests in detecting high-risk HPV genotypes in specimens from women with previous abnormal Pap smear results. J Clin Microbiol 2007;45:2130-7.
32. Giuliani L, Coletti A, Syrjänen K, Favalli C, Ciotti M. Comparison of DNA sequencing and Roche Linear array in human papillomavirus (HPV) genotyping. Anticancer Res 2006;26:3939-41.
33. Bosch FX, Manos MM, Muñoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) study group. J Natl Cancer Inst 1995;87:796-802.